<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02781610</url>
  </required_header>
  <id_info>
    <org_study_id>STOP2-IP-15</org_study_id>
    <nct_id>NCT02781610</nct_id>
  </id_info>
  <brief_title>Standardized Treatment of Pulmonary Exacerbations II</brief_title>
  <acronym>STOP2</acronym>
  <official_title>Standardized Treatment of Pulmonary Exacerbations II (STOP2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chris Goss</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cystic Fibrosis Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CF Therapeutics Development Network Coordinating Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seattle Children's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cystic fibrosis (CF), a life-shortening genetic disease, is marked by acute episodes during&#xD;
      which symptoms of lung infection increase and lung function decreases. These pulmonary&#xD;
      exacerbations are treated with varying antibiotics for varying time periods based on needs&#xD;
      determined by individual patients, their families, and the health care providers. Cystic&#xD;
      fibrosis pulmonary guidelines for the treatment of pulmonary exacerbation published by the&#xD;
      Cystic Fibrosis Foundation (CFF) in 2009 provided recommendations for treatment and also&#xD;
      identified key questions for which additional studies were needed.&#xD;
&#xD;
      A strong desire among clinicians to reduce treatment durations (and reduce cost,&#xD;
      inconvenience, and potential toxicities) is in conflict with belief that patients not&#xD;
      responding robustly to treatment might benefit from extending treatment.&#xD;
&#xD;
      This randomized, controlled, open-label study is designed to evaluate the efficacy and safety&#xD;
      of differing durations of IV treatment, given in the hospital or at home for a pulmonary&#xD;
      exacerbation in adult patients with CF.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will assess the non-inferiority of 10 days versus 14 days treatment duration among&#xD;
      patients who have an early robust improvement (ERR subjects) and the superiority of 21 days&#xD;
      versus 14 days treatment duration among the subjects who do not meet the definition of ERR&#xD;
      (non-ERR; NERR).&#xD;
&#xD;
      Subjects will undergo pulmonary function testing (spirometry) and complete a respiratory&#xD;
      symptom score [Chronic Respiratory Infection Symptom Score (CRISS)] at initiation of IV&#xD;
      treatment (Baseline/ Visit 1) and at Day 7-10 (Visit 2). At Visit 2, subjects will be&#xD;
      allocated to groups ERR or NERR based on their initial clinical response as determined by the&#xD;
      change in forced expiratory volume in 1 second (FEV1; percent of predicted) and CRISS from&#xD;
      Baseline and then randomized to an IV treatment duration (nested within group).&#xD;
&#xD;
      ERR subjects [≥8% predicted improvement in FEV1 from Visit 1 to Visit 2 and CRISS reduction&#xD;
      of ≥11 points from Visit 1 to Visit 2] will be randomized 1:1 to either 10 days or 14 days&#xD;
      total IV antibiotic treatment duration. Remaining (NERR) subjects will be randomized 1:1 to&#xD;
      receive either 14 or 21 days total IV antibiotic treatment duration. All subjects will be&#xD;
      evaluated again at Visit 3, 14 days following scheduled completion of IV antibiotic&#xD;
      treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Actual">March 6, 2020</completion_date>
  <primary_completion_date type="Actual">March 6, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute Change in FEV1 % Predicted From Visit 1 to Visit 3 Between ERR-10 Day and ERR-14 Day</measure>
    <time_frame>Start of IV antibiotic treatment to 14 days after the end of IV antibiotic treatment</time_frame>
    <description>Absolute change in FEV1 % predicted from baseline/visit 1 (start of IV antibiotic treatment) to last study visit/visit 3 (14 days after the end of IV antibiotic treatment).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Absolute Change in FEV1 % Predicted From Visit 1 to Visit 3 Between NERR-14 Day and NERR-21</measure>
    <time_frame>Start of IV antibiotic treatment to14 days after the end of IV antibiotic treatment</time_frame>
    <description>Absolute change in FEV1 % predicted from baseline/visit 1 (start of IV antibiotic treatment) to last study visit/visit 3 (14 days after the end of IV antibiotic treatment).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in CRISS From Visit 1 to Visit 3 Between ERR-10 Day and ERR-14 Day</measure>
    <time_frame>Start of IV antibiotic treatment to14 days after the end of IV antibiotic treatment</time_frame>
    <description>Absolute change in respiratory symptoms, as measured by the the Cystic Fibrosis Respiratory Symptoms Diary-Chronic Respiratory Infection Symptom Severity Score (CFRSD-CRISS), from baseline/visit 1 (start of IV antibiotic treatment) to last study visit/visit 3 (14 days after the end of IV antibiotic treatment). The Diary asks a participant to state the extent of their 8 respiratory symptoms: difficulty breathing, feverishness, tiredness, chills or sweats, coughing, coughing up mucus, tightness in the chest and wheezing. Each respiratory symptom is assigned a score from 0-4 based on the response, with zero corresponding to the absence of the symptom and four corresponding to symptom being present 'a great deal' or 'extremely'. A summed score (range from 0-24) is calculated for each participant and converted to a final score with a range of 0 to 100, where the lowest scores indicate improvement of symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CRISS From Visit 1 to Visit 3 Between NERR-14 Day and NERR-21 Day</measure>
    <time_frame>Start of IV antibiotic treatment to14 days after the end of IV antibiotic treatment</time_frame>
    <description>Absolute change in respiratory symptoms, as measured by the the Cystic Fibrosis Respiratory Symptoms Diary-Chronic Respiratory Infection Symptom Severity Score (CFRSD-CRISS), from baseline/visit 1 (start of IV antibiotic treatment) to last study visit/visit 3 (14 days after the end of IV antibiotic treatment). The Diary asks a participant to state the extent of their 8 respiratory symptoms: difficulty breathing, feverishness, tiredness, chills or sweats, coughing, coughing up mucus, tightness in the chest and wheezing. Each respiratory symptom is assigned a score from 0-4 based on the response, with zero corresponding to the absence of the symptom and four corresponding to symptom being present 'a great deal' or 'extremely'. A summed score (range from 0-24) is calculated for each participant and converted to a final score with a range of 0 to 100, where the lowest scores indicate improvement of symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Weight From Visit 1 to Visit 3 Between ERR-10 Day and ERR-14 Day</measure>
    <time_frame>Start of IV antibiotic treatment to14 days after the end of IV antibiotic treatment</time_frame>
    <description>Absolute change in weight (kg) from baseline/visit 1 (start of IV antibiotic treatment) to last study visit/visit 3 (14 days after the end of IV antibiotic treatment).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Weight From Visit 1 to Visit 3 Between NERR-14 Day and NERR-21 Day</measure>
    <time_frame>Start of IV antibiotic treatment to14 days after the end of IV antibiotic treatment</time_frame>
    <description>Absolute change in weight (kg) from baseline/visit 1 (start of IV antibiotic treatment) to last study visit/visit 3 (14 days after the end of IV antibiotic treatment).</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">982</enrollment>
  <condition>Pulmonary Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>ERR-10</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>ERR treatment duration - 10 Day Standard of care IV antibiotic(s) will be selected by the treating physician. Duration of treatment is the assigned intervention.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ERR-14</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>ERR treatment duration - 14 Day Standard of care IV antibiotic(s) will be selected by the treating physician. Duration of treatment is the assigned intervention.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NERR-14</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>NERR treatment duration - 14 Day Standard of care IV antibiotic(s) will be selected by the treating physician. Duration of treatment is the assigned intervention.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NERR-21</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>NERR treatment duration - 21 Day Standard of care IV antibiotic(s) will be selected by the treating physician. Duration of treatment is the assigned intervention.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard of care IV antibiotic(s)</intervention_name>
    <description>IV antibiotics will be selected by the treating physician following standard of care. Duration of treatment is the assigned intervention.</description>
    <arm_group_label>ERR-10</arm_group_label>
    <arm_group_label>ERR-14</arm_group_label>
    <arm_group_label>NERR-14</arm_group_label>
    <arm_group_label>NERR-21</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Male or female ≥18 years of age at Visit 1&#xD;
&#xD;
          -  Documentation of a CF diagnosis&#xD;
&#xD;
          -  Enrolled in the Cystic Fibrosis Foundation National Patient Registry (CFFNPR) prior to&#xD;
             Visit 1 (US sites only)&#xD;
&#xD;
          -  At the time of Visit 1, there is a plan to initiate IV antibiotics for a pulmonary&#xD;
             exacerbation&#xD;
&#xD;
          -  Performed spirometry at Visit 1 and Visit 2 and willing to perform spirometry at Visit&#xD;
             3&#xD;
&#xD;
          -  Completed the CRISS questionnaire at Visit 1 and Visit 2 and willing to complete the&#xD;
             Cystic Fibrosis Respiratory Symptoms Diary (CFRSD) questionnaire at Visit 3&#xD;
&#xD;
          -  Willing to adhere to a specific treatment duration determined by initial response to&#xD;
             treatment and subsequent randomization&#xD;
&#xD;
          -  Willing to return for follow up Visit 3&#xD;
&#xD;
          -  Written informed consent obtained from the subject or subject's legal representative&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Key Exclusion Criteria&#xD;
&#xD;
          -  Previous randomization in this study&#xD;
&#xD;
          -  Treatment with IV antibiotics in the 6 weeks prior to Visit 1&#xD;
&#xD;
          -  Admission to the intensive care unit for current pulmonary exacerbation in the two&#xD;
             weeks prior to Visit 2, unless admission was due to a desensitization protocol&#xD;
&#xD;
          -  Pneumothorax in the two weeks prior to Visit 2&#xD;
&#xD;
          -  Primary diagnosis for current hospitalization is unrelated to worsening lower&#xD;
             respiratory symptoms (e.g., pulmonary clean out, distal intestinal obstruction&#xD;
             syndrome (DIOS), sinusitis)&#xD;
&#xD;
          -  Massive hemoptysis defined as &gt; 250 cc in a 24 hour period or 100 cc/day over 4&#xD;
             consecutive days occurring in the two weeks prior to Visit 2&#xD;
&#xD;
          -  Current pulmonary exacerbation thought to be due to allergic bronchopulmonary&#xD;
             aspergillosis (ABPA)&#xD;
&#xD;
          -  At Visit 1, receiving ongoing treatment with a duration of more than 2 weeks with&#xD;
             prednisone equivalent to &gt;10mg/day&#xD;
&#xD;
          -  History of solid organ transplantation&#xD;
&#xD;
          -  Receiving antimicrobial therapy to treat non-tuberculous mycobacterium (e.g., M.&#xD;
             abscessus, M. avium complex) in the two weeks prior to Visit 2&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chris Goss, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Patrick Flume, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Children's Hospital Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Alaska Medical Center</name>
      <address>
        <city>Anchorage</city>
        <state>Alaska</state>
        <zip>99519-6604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC San Diego Medical Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lucile S. Packard Children's Hospital</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Davis, Health System</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Jewish Health</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hartford Hospital</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale New Haven Hospital</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shands Hospital</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Joe DiMaggio Children's Hospital (Adult)</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Augusta University Medical Center</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Regional Medical Center</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Francis Medical Center</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Hospital, Indiana University Health</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Kansas Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Children's Hospital (BCH)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Massachusetts Memorial Health Care (Worcester, MA)</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Health System</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-5212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Detroit Medical Center; Harper University Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Louis University Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Louis Washington University Adult - Barnes-Jewish Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Billings Clinic</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59107-7000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dartmouth Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monmouth Medical Center</name>
      <address>
        <city>Long Branch</city>
        <state>New Jersey</state>
        <zip>07740</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Morristown Medical Center</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07960</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert Wood Johnson University Hospital (New Brunswick, NJ)</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women and Children's Hospital of Buffalo</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14222</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Long Island Jewish Medical Center</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Highland Hospital; Strong Memorial Hospital</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate Medical University Hospital</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Medical College</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Carolina Children's Hospital</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27517</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Baptist Medical Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akron Children's Hospital</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Cleveland</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dayton Children's Hospital</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina; Medical University of South Carolina Children's Hospital</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor St. Lukes Medical Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Center at Tyler</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75708-3154</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Vermont Medical Center Inc.</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia Health System</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Virginia (Richmond, VA)</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ruby Memorial Hospital</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Hospital Center</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Froedtert Hospital</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Calgary Canada Adult CF Clinic</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>May 12, 2016</study_first_submitted>
  <study_first_submitted_qc>May 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 24, 2016</study_first_posted>
  <results_first_submitted>March 11, 2021</results_first_submitted>
  <results_first_submitted_qc>March 11, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 8, 2021</results_first_posted>
  <last_update_submitted>April 28, 2021</last_update_submitted>
  <last_update_submitted_qc>April 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Seattle Children's Hospital</investigator_affiliation>
    <investigator_full_name>Chris Goss</investigator_full_name>
    <investigator_title>Professor of Medicine and Pediatrics</investigator_title>
  </responsible_party>
  <keyword>Cystic fibrosis</keyword>
  <keyword>Pulmonary exacerbation</keyword>
  <keyword>Antibiotic</keyword>
  <keyword>Treatment duration</keyword>
  <keyword>Lung infection</keyword>
  <keyword>Cystic Fibrosis Foundation</keyword>
  <keyword>Cystic Fibrosis Foundation National Patient Registry</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 2, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/10/NCT02781610/Prot_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 14, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/10/NCT02781610/SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>ERR-10</title>
          <description>ERR treatment duration - 10 Day Standard of care IV antibiotic(s) will be selected by the treating physician. Duration of treatment is the assigned intervention.&#xD;
Standard of care IV antibiotic(s): IV antibiotics will be selected by the treating physician following standard of care. Duration of treatment is the assigned intervention.</description>
        </group>
        <group group_id="P2">
          <title>ERR-14</title>
          <description>ERR treatment duration - 14 Day Standard of care IV antibiotic(s) will be selected by the treating physician. Duration of treatment is the assigned intervention.&#xD;
Standard of care IV antibiotic(s): IV antibiotics will be selected by the treating physician following standard of care. Duration of treatment is the assigned intervention.</description>
        </group>
        <group group_id="P3">
          <title>NERR-14</title>
          <description>NERR treatment duration - 14 Day Standard of care IV antibiotic(s) will be selected by the treating physician. Duration of treatment is the assigned intervention.&#xD;
Standard of care IV antibiotic(s): IV antibiotics will be selected by the treating physician following standard of care. Duration of treatment is the assigned intervention.</description>
        </group>
        <group group_id="P4">
          <title>NERR-21</title>
          <description>NERR treatment duration - 21 Day Standard of care IV antibiotic(s) will be selected by the treating physician. Duration of treatment is the assigned intervention.&#xD;
Standard of care IV antibiotic(s): IV antibiotics will be selected by the treating physician following standard of care. Duration of treatment is the assigned intervention.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="140"/>
                <participants group_id="P2" count="137"/>
                <participants group_id="P3" count="353"/>
                <participants group_id="P4" count="352"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="134"/>
                <participants group_id="P2" count="130"/>
                <participants group_id="P3" count="336"/>
                <participants group_id="P4" count="323"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="17"/>
                <participants group_id="P4" count="29"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Analysis for the ERR arms (ERR-10, ERR-14) was done on the per-protocol (PP) population. Analysis for the NERR arms (NERR-14, NERR-21) was done on the intent-to-treat (ITT) population. Caution: Analysis was not done on the combined total of all four treatment duration arms. Interpreting the total column is inappropriate for this study design.</population>
      <group_list>
        <group group_id="B1">
          <title>ERR-10</title>
          <description>ERR treatment duration - 10 Day Standard of care IV antibiotic(s) will be selected by the treating physician. Duration of treatment is the assigned intervention.&#xD;
Standard of care IV antibiotic(s): IV antibiotics will be selected by the treating physician following standard of care. Duration of treatment is the assigned intervention.</description>
        </group>
        <group group_id="B2">
          <title>ERR-14</title>
          <description>ERR treatment duration - 14 Day Standard of care IV antibiotic(s) will be selected by the treating physician. Duration of treatment is the assigned intervention.&#xD;
Standard of care IV antibiotic(s): IV antibiotics will be selected by the treating physician following standard of care. Duration of treatment is the assigned intervention.</description>
        </group>
        <group group_id="B3">
          <title>NERR-14</title>
          <description>NERR treatment duration - 14 Day Standard of care IV antibiotic(s) will be selected by the treating physician. Duration of treatment is the assigned intervention.&#xD;
Standard of care IV antibiotic(s): IV antibiotics will be selected by the treating physician following standard of care. Duration of treatment is the assigned intervention.</description>
        </group>
        <group group_id="B4">
          <title>NERR-21</title>
          <description>NERR treatment duration - 21 Day Standard of care IV antibiotic(s) will be selected by the treating physician. Duration of treatment is the assigned intervention.&#xD;
Standard of care IV antibiotic(s): IV antibiotics will be selected by the treating physician following standard of care. Duration of treatment is the assigned intervention.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="107"/>
            <count group_id="B2" value="107"/>
            <count group_id="B3" value="353"/>
            <count group_id="B4" value="352"/>
            <count group_id="B5" value="919"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.6" spread="6.34"/>
                    <measurement group_id="B2" value="27.1" spread="8.89"/>
                    <measurement group_id="B3" value="31.8" spread="10.52"/>
                    <measurement group_id="B4" value="31.5" spread="9.63"/>
                    <measurement group_id="B5" value="30.6" spread="9.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="192"/>
                    <measurement group_id="B4" value="171"/>
                    <measurement group_id="B5" value="462"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="161"/>
                    <measurement group_id="B4" value="181"/>
                    <measurement group_id="B5" value="457"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="63"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="99"/>
                    <measurement group_id="B2" value="98"/>
                    <measurement group_id="B3" value="327"/>
                    <measurement group_id="B4" value="332"/>
                    <measurement group_id="B5" value="856"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="98"/>
                    <measurement group_id="B2" value="100"/>
                    <measurement group_id="B3" value="335"/>
                    <measurement group_id="B4" value="322"/>
                    <measurement group_id="B5" value="855"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cystic Fibrosis (CF) Genotype</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Delta F508 Homozygous</title>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="171"/>
                    <measurement group_id="B4" value="174"/>
                    <measurement group_id="B5" value="446"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Delta F508 Heterozygous</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="127"/>
                    <measurement group_id="B4" value="135"/>
                    <measurement group_id="B5" value="347"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other/Unknown</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="55"/>
                    <measurement group_id="B4" value="43"/>
                    <measurement group_id="B5" value="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Forced Expiratory Volume in 1 second (FEV1)</title>
          <units>liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.9" spread="0.80"/>
                    <measurement group_id="B2" value="1.8" spread="0.83"/>
                    <measurement group_id="B3" value="1.8" spread="0.83"/>
                    <measurement group_id="B4" value="1.8" spread="0.76"/>
                    <measurement group_id="B5" value="1.8" spread="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>FEV1 (% Predicted) Distribution</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;50%</title>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="192"/>
                    <measurement group_id="B4" value="194"/>
                    <measurement group_id="B5" value="507"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=50%</title>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="161"/>
                    <measurement group_id="B4" value="158"/>
                    <measurement group_id="B5" value="412"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of PEx in last year</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>0 - 1</title>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="145"/>
                    <measurement group_id="B4" value="144"/>
                    <measurement group_id="B5" value="377"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=2</title>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="208"/>
                    <measurement group_id="B4" value="208"/>
                    <measurement group_id="B5" value="542"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>IV Antibiotic Treatment Location Prior to Randomization</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Any Nights in Hospital</title>
                  <measurement_list>
                    <measurement group_id="B1" value="92"/>
                    <measurement group_id="B2" value="90"/>
                    <measurement group_id="B3" value="265"/>
                    <measurement group_id="B4" value="266"/>
                    <measurement group_id="B5" value="713"/>
                  </measurement_list>
                </category>
                <category>
                  <title>All at Home</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="88"/>
                    <measurement group_id="B4" value="86"/>
                    <measurement group_id="B5" value="206"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Systemic Corticosteroid Use</title>
          <description>Indication of systemic corticosteroids initiated on or after day of IV antibiotics start and before randomization.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="41"/>
                    <measurement group_id="B5" value="87"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="94"/>
                    <measurement group_id="B2" value="97"/>
                    <measurement group_id="B3" value="330"/>
                    <measurement group_id="B4" value="311"/>
                    <measurement group_id="B5" value="832"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Absolute Change in FEV1 % Predicted From Visit 1 to Visit 3 Between ERR-10 Day and ERR-14 Day</title>
        <description>Absolute change in FEV1 % predicted from baseline/visit 1 (start of IV antibiotic treatment) to last study visit/visit 3 (14 days after the end of IV antibiotic treatment).</description>
        <time_frame>Start of IV antibiotic treatment to 14 days after the end of IV antibiotic treatment</time_frame>
        <population>Includes only participants within the ERR treatment group and per-protocol population, with FEV1 measurements at baseline and last study visit.</population>
        <group_list>
          <group group_id="O1">
            <title>ERR-10</title>
            <description>ERR treatment duration - 10 Day Standard of care IV antibiotic(s) will be selected by the treating physician. Duration of treatment is the assigned intervention.&#xD;
Standard of care IV antibiotic(s): IV antibiotics will be selected by the treating physician following standard of care. Duration of treatment is the assigned intervention.</description>
          </group>
          <group group_id="O2">
            <title>ERR-14</title>
            <description>ERR treatment duration - 14 Day Standard of care IV antibiotic(s) will be selected by the treating physician. Duration of treatment is the assigned intervention.&#xD;
Standard of care IV antibiotic(s): IV antibiotics will be selected by the treating physician following standard of care. Duration of treatment is the assigned intervention.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change in FEV1 % Predicted From Visit 1 to Visit 3 Between ERR-10 Day and ERR-14 Day</title>
          <description>Absolute change in FEV1 % predicted from baseline/visit 1 (start of IV antibiotic treatment) to last study visit/visit 3 (14 days after the end of IV antibiotic treatment).</description>
          <population>Includes only participants within the ERR treatment group and per-protocol population, with FEV1 measurements at baseline and last study visit.</population>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="107"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.30" spread="9.65"/>
                    <measurement group_id="O2" value="13.83" spread="9.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The ERR non-inferiority test was a priori designed to be conducted on the per-protocol (PP) population for 93% power assuming 2-sided alpha=0.05 with 155 PP participants per arm. Difference between ERR treatment duration arms is ERR-10 - ERR-14.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority margin is -3.5%.</non_inferiority_desc>
            <p_value>0.0164</p_value>
            <method>ANOVA</method>
            <method_desc>Adjusted for four dichotomous randomization strata.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.3</ci_lower_limit>
            <ci_upper_limit>2.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Absolute Change in FEV1 % Predicted From Visit 1 to Visit 3 Between NERR-14 Day and NERR-21</title>
        <description>Absolute change in FEV1 % predicted from baseline/visit 1 (start of IV antibiotic treatment) to last study visit/visit 3 (14 days after the end of IV antibiotic treatment).</description>
        <time_frame>Start of IV antibiotic treatment to14 days after the end of IV antibiotic treatment</time_frame>
        <population>Includes only participants within the NERR treatment group and intent-to-treat population, with FEV1 measurements at baseline and last study visit.</population>
        <group_list>
          <group group_id="O1">
            <title>NERR-14</title>
            <description>NERR treatment duration - 14 Day Standard of care IV antibiotic(s) will be selected by the treating physician. Duration of treatment is the assigned intervention.&#xD;
Standard of care IV antibiotic(s): IV antibiotics will be selected by the treating physician following standard of care. Duration of treatment is the assigned intervention.</description>
          </group>
          <group group_id="O2">
            <title>NERR-21</title>
            <description>NERR treatment duration - 21 Day Standard of care IV antibiotic(s) will be selected by the treating physician. Duration of treatment is the assigned intervention.&#xD;
Standard of care IV antibiotic(s): IV antibiotics will be selected by the treating physician following standard of care. Duration of treatment is the assigned intervention.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change in FEV1 % Predicted From Visit 1 to Visit 3 Between NERR-14 Day and NERR-21</title>
          <description>Absolute change in FEV1 % predicted from baseline/visit 1 (start of IV antibiotic treatment) to last study visit/visit 3 (14 days after the end of IV antibiotic treatment).</description>
          <population>Includes only participants within the NERR treatment group and intent-to-treat population, with FEV1 measurements at baseline and last study visit.</population>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="331"/>
                <count group_id="O2" value="322"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.60" spread="8.22"/>
                    <measurement group_id="O2" value="3.53" spread="7.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The NERR superiority test was a priori designed to be conducted on the Intent-to-Treat (ITT) population for 91% power to detect a 2.5% difference, assuming 2-sided alpha=0.05 with 285 ITT participants per arm. Difference between NERR treatment duration arms is NERR-21 - NERR-14.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.568</p_value>
            <method>ANOVA</method>
            <method_desc>Adjusted for four dichotomous randomization strata.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.3</ci_lower_limit>
            <ci_upper_limit>1.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in CRISS From Visit 1 to Visit 3 Between ERR-10 Day and ERR-14 Day</title>
        <description>Absolute change in respiratory symptoms, as measured by the the Cystic Fibrosis Respiratory Symptoms Diary-Chronic Respiratory Infection Symptom Severity Score (CFRSD-CRISS), from baseline/visit 1 (start of IV antibiotic treatment) to last study visit/visit 3 (14 days after the end of IV antibiotic treatment). The Diary asks a participant to state the extent of their 8 respiratory symptoms: difficulty breathing, feverishness, tiredness, chills or sweats, coughing, coughing up mucus, tightness in the chest and wheezing. Each respiratory symptom is assigned a score from 0-4 based on the response, with zero corresponding to the absence of the symptom and four corresponding to symptom being present 'a great deal' or 'extremely'. A summed score (range from 0-24) is calculated for each participant and converted to a final score with a range of 0 to 100, where the lowest scores indicate improvement of symptoms.</description>
        <time_frame>Start of IV antibiotic treatment to14 days after the end of IV antibiotic treatment</time_frame>
        <population>Includes only participants within the ERR treatment group and per-protocol (PP) population, with CRISS measurements at baseline and last study visit.</population>
        <group_list>
          <group group_id="O1">
            <title>ERR-10</title>
            <description>ERR treatment duration - 10 Day Standard of care IV antibiotic(s) will be selected by the treating physician. Duration of treatment is the assigned intervention.&#xD;
Standard of care IV antibiotic(s): IV antibiotics will be selected by the treating physician following standard of care. Duration of treatment is the assigned intervention.</description>
          </group>
          <group group_id="O2">
            <title>ERR-14</title>
            <description>ERR treatment duration - 14 Day Standard of care IV antibiotic(s) will be selected by the treating physician. Duration of treatment is the assigned intervention.&#xD;
Standard of care IV antibiotic(s): IV antibiotics will be selected by the treating physician following standard of care. Duration of treatment is the assigned intervention.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in CRISS From Visit 1 to Visit 3 Between ERR-10 Day and ERR-14 Day</title>
          <description>Absolute change in respiratory symptoms, as measured by the the Cystic Fibrosis Respiratory Symptoms Diary-Chronic Respiratory Infection Symptom Severity Score (CFRSD-CRISS), from baseline/visit 1 (start of IV antibiotic treatment) to last study visit/visit 3 (14 days after the end of IV antibiotic treatment). The Diary asks a participant to state the extent of their 8 respiratory symptoms: difficulty breathing, feverishness, tiredness, chills or sweats, coughing, coughing up mucus, tightness in the chest and wheezing. Each respiratory symptom is assigned a score from 0-4 based on the response, with zero corresponding to the absence of the symptom and four corresponding to symptom being present 'a great deal' or 'extremely'. A summed score (range from 0-24) is calculated for each participant and converted to a final score with a range of 0 to 100, where the lowest scores indicate improvement of symptoms.</description>
          <population>Includes only participants within the ERR treatment group and per-protocol (PP) population, with CRISS measurements at baseline and last study visit.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.2" spread="13.21"/>
                    <measurement group_id="O2" value="-25.3" spread="12.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Difference between ERR treatment duration arms is ERR-10 - ERR-14.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.546</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.4</ci_lower_limit>
            <ci_upper_limit>4.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in CRISS From Visit 1 to Visit 3 Between NERR-14 Day and NERR-21 Day</title>
        <description>Absolute change in respiratory symptoms, as measured by the the Cystic Fibrosis Respiratory Symptoms Diary-Chronic Respiratory Infection Symptom Severity Score (CFRSD-CRISS), from baseline/visit 1 (start of IV antibiotic treatment) to last study visit/visit 3 (14 days after the end of IV antibiotic treatment). The Diary asks a participant to state the extent of their 8 respiratory symptoms: difficulty breathing, feverishness, tiredness, chills or sweats, coughing, coughing up mucus, tightness in the chest and wheezing. Each respiratory symptom is assigned a score from 0-4 based on the response, with zero corresponding to the absence of the symptom and four corresponding to symptom being present 'a great deal' or 'extremely'. A summed score (range from 0-24) is calculated for each participant and converted to a final score with a range of 0 to 100, where the lowest scores indicate improvement of symptoms.</description>
        <time_frame>Start of IV antibiotic treatment to14 days after the end of IV antibiotic treatment</time_frame>
        <population>Includes only participants within the NERR treatment group and intent-to-treat (ITT) population, with CRISS measurements at baseline and last study visit.</population>
        <group_list>
          <group group_id="O1">
            <title>NERR-14</title>
            <description>NERR treatment duration - 14 Day Standard of care IV antibiotic(s) will be selected by the treating physician. Duration of treatment is the assigned intervention.&#xD;
Standard of care IV antibiotic(s): IV antibiotics will be selected by the treating physician following standard of care. Duration of treatment is the assigned intervention.</description>
          </group>
          <group group_id="O2">
            <title>NERR-21</title>
            <description>NERR treatment duration - 21 Day Standard of care IV antibiotic(s) will be selected by the treating physician. Duration of treatment is the assigned intervention.&#xD;
Standard of care IV antibiotic(s): IV antibiotics will be selected by the treating physician following standard of care. Duration of treatment is the assigned intervention.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in CRISS From Visit 1 to Visit 3 Between NERR-14 Day and NERR-21 Day</title>
          <description>Absolute change in respiratory symptoms, as measured by the the Cystic Fibrosis Respiratory Symptoms Diary-Chronic Respiratory Infection Symptom Severity Score (CFRSD-CRISS), from baseline/visit 1 (start of IV antibiotic treatment) to last study visit/visit 3 (14 days after the end of IV antibiotic treatment). The Diary asks a participant to state the extent of their 8 respiratory symptoms: difficulty breathing, feverishness, tiredness, chills or sweats, coughing, coughing up mucus, tightness in the chest and wheezing. Each respiratory symptom is assigned a score from 0-4 based on the response, with zero corresponding to the absence of the symptom and four corresponding to symptom being present 'a great deal' or 'extremely'. A summed score (range from 0-24) is calculated for each participant and converted to a final score with a range of 0 to 100, where the lowest scores indicate improvement of symptoms.</description>
          <population>Includes only participants within the NERR treatment group and intent-to-treat (ITT) population, with CRISS measurements at baseline and last study visit.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="335"/>
                <count group_id="O2" value="322"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.1" spread="13.74"/>
                    <measurement group_id="O2" value="-16.7" spread="14.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Difference between NERR treatment duration arms is NERR-21 - NERR-14.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.140</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.7</ci_lower_limit>
            <ci_upper_limit>0.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Weight From Visit 1 to Visit 3 Between ERR-10 Day and ERR-14 Day</title>
        <description>Absolute change in weight (kg) from baseline/visit 1 (start of IV antibiotic treatment) to last study visit/visit 3 (14 days after the end of IV antibiotic treatment).</description>
        <time_frame>Start of IV antibiotic treatment to14 days after the end of IV antibiotic treatment</time_frame>
        <population>Includes only participants within the ERR treatment group and per-protocol (PP) population, with weight measurements at baseline and last study visit.</population>
        <group_list>
          <group group_id="O1">
            <title>ERR-10</title>
            <description>ERR treatment duration - 10 Day Standard of care IV antibiotic(s) will be selected by the treating physician. Duration of treatment is the assigned intervention.&#xD;
Standard of care IV antibiotic(s): IV antibiotics will be selected by the treating physician following standard of care. Duration of treatment is the assigned intervention.</description>
          </group>
          <group group_id="O2">
            <title>ERR-14</title>
            <description>ERR treatment duration - 14 Day Standard of care IV antibiotic(s) will be selected by the treating physician. Duration of treatment is the assigned intervention.&#xD;
Standard of care IV antibiotic(s): IV antibiotics will be selected by the treating physician following standard of care. Duration of treatment is the assigned intervention.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Weight From Visit 1 to Visit 3 Between ERR-10 Day and ERR-14 Day</title>
          <description>Absolute change in weight (kg) from baseline/visit 1 (start of IV antibiotic treatment) to last study visit/visit 3 (14 days after the end of IV antibiotic treatment).</description>
          <population>Includes only participants within the ERR treatment group and per-protocol (PP) population, with weight measurements at baseline and last study visit.</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="107"/>
                <count group_id="O2" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="2.18"/>
                    <measurement group_id="O2" value="1.5" spread="2.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Difference between ERR treatment duration arms is ERR-10 - ERR-14.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.563</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.42</ci_lower_limit>
            <ci_upper_limit>0.77</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Weight From Visit 1 to Visit 3 Between NERR-14 Day and NERR-21 Day</title>
        <description>Absolute change in weight (kg) from baseline/visit 1 (start of IV antibiotic treatment) to last study visit/visit 3 (14 days after the end of IV antibiotic treatment).</description>
        <time_frame>Start of IV antibiotic treatment to14 days after the end of IV antibiotic treatment</time_frame>
        <population>Includes only participants within the NERR treatment group and intent-to-treat (ITT) population, with weight measurements at baseline and last study visit.</population>
        <group_list>
          <group group_id="O1">
            <title>NERR-14</title>
            <description>NERR treatment duration - 14 Day Standard of care IV antibiotic(s) will be selected by the treating physician. Duration of treatment is the assigned intervention.&#xD;
Standard of care IV antibiotic(s): IV antibiotics will be selected by the treating physician following standard of care. Duration of treatment is the assigned intervention.</description>
          </group>
          <group group_id="O2">
            <title>NERR-21</title>
            <description>NERR treatment duration - 21 Day Standard of care IV antibiotic(s) will be selected by the treating physician. Duration of treatment is the assigned intervention.&#xD;
Standard of care IV antibiotic(s): IV antibiotics will be selected by the treating physician following standard of care. Duration of treatment is the assigned intervention.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Weight From Visit 1 to Visit 3 Between NERR-14 Day and NERR-21 Day</title>
          <description>Absolute change in weight (kg) from baseline/visit 1 (start of IV antibiotic treatment) to last study visit/visit 3 (14 days after the end of IV antibiotic treatment).</description>
          <population>Includes only participants within the NERR treatment group and intent-to-treat (ITT) population, with weight measurements at baseline and last study visit.</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="333"/>
                <count group_id="O2" value="320"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="2.16"/>
                    <measurement group_id="O2" value="0.8" spread="2.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Difference between NERR treatment duration arms is NERR-21 - NERR-14.</non_inferiority_desc>
            <p_value>0.083</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.29</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.04</ci_lower_limit>
            <ci_upper_limit>0.61</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>For Serious Adverse Events (SAEs): Informed consent to final study visit (14 days after the end of IV antibiotic treatment). For all Other (Not Including Serious) AEs: Randomization to final study visit. Final study visit is Day 25 for ERR-10 arm, Day 29 for ERR-14 arm and NERR-14 arm, and Day 36 for NERR-21 arm.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>ERR-10</title>
          <description>ERR treatment duration - 10 Day Standard of care IV antibiotic(s) will be selected by the treating physician. Duration of treatment is the assigned intervention.&#xD;
Standard of care IV antibiotic(s): IV antibiotics will be selected by the treating physician following standard of care. Duration of treatment is the assigned intervention.</description>
        </group>
        <group group_id="E2">
          <title>ERR-14</title>
          <description>ERR treatment duration - 14 Day Standard of care IV antibiotic(s) will be selected by the treating physician. Duration of treatment is the assigned intervention.&#xD;
Standard of care IV antibiotic(s): IV antibiotics will be selected by the treating physician following standard of care. Duration of treatment is the assigned intervention.</description>
        </group>
        <group group_id="E3">
          <title>NERR-14</title>
          <description>NERR treatment duration - 14 Day Standard of care IV antibiotic(s) will be selected by the treating physician. Duration of treatment is the assigned intervention.&#xD;
Standard of care IV antibiotic(s): IV antibiotics will be selected by the treating physician following standard of care. Duration of treatment is the assigned intervention.</description>
        </group>
        <group group_id="E4">
          <title>NERR-21</title>
          <description>NERR treatment duration - 21 Day Standard of care IV antibiotic(s) will be selected by the treating physician. Duration of treatment is the assigned intervention.&#xD;
Standard of care IV antibiotic(s): IV antibiotics will be selected by the treating physician following standard of care. Duration of treatment is the assigned intervention.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="353"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Haemolytic anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Distal intestinal obstruction syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Gastrointestinal viral infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Infective pulmonary exacerbation of cystic fibrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="353"/>
                <counts group_id="E4" events="10" subjects_affected="9" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Panic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="353"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="353"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="353"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infective pulmonary exacerbation of cystic fibrosis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="140"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="137"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="353"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Analysis was not done on the combined total of all four treatment duration arms. Interpreting the total column within demographics is inappropriate for this study design.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Michelle Skalland (Biostatistician)</name_or_title>
      <organization>Seattle Children's</organization>
      <phone>206-884-7519</phone>
      <email>michelle.skalland@seattlechildrens.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

